Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

LESSONS LEARNED. Weekly nanoparticle albumin‐bound‐paclitaxel (75 mg/m(2)) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non‐small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Miyauchi, Eisaku, Inoue, Akira, Usui, Kazuhiro, Sugawara, Shunichi, Maemondo, Makoto, Saito, Heisuke, Fujita, Yuka, Kato, Terufumi, Suzuki, Toshiro, Harada, Toshiyuki, Watanabe, Hiroshi, Nakagawa, Taku, Ichinose, Masakazu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2017
Konular:
Clinical Trial Results
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469596/
https://ncbi.nlm.nih.gov/pubmed/28526722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0059
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller